Hyperlipidemia - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 89

Hyperlipidemia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Hyperlipidemia - Pipeline Review, H1 2012', provides an overview of the Hyperlipidemia therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia. 'Hyperlipidemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hyperlipidemia.
- A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hyperlipidemia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Hyperlipidemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hyperlipidemia Therapeutic Products under Development, Key Players in Hyperlipidemia Therapeutics, Hyperlipidemia Pipeline Overview, Hyperlipidemia Pipeline, Hyperlipidemia Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperlipidemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hyperlipidemia
Hyperlipidemia Therapeutics under Development by Companies
Hyperlipidemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hyperlipidemia Therapeutics – Products under Development by Companies
Hyperlipidemia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Hyperlipidemia Therapeutics Development
Takeda Pharmaceutical Company Limited
Samyang Corporation
Daewoong Pharmaceutical Co., Ltd.
Dr. Reddy's Laboratories Limited
Aegerion Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
WhanIn Pharmaceutical Co., Ltd.
Hanall Pharmaceutical Co., Ltd.
Circ Pharma Limited
Ferrer Internacional S.A.
Esperion Therapeutics, Inc.
CORTRIA Corporation
Hyperlipidemia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
TAK-085 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMO-3100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMD5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRES Pravastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DRL 17822 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL 040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRIA-662 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETC-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atorvastatin for HIV Infections and Hyperlipidemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acetylsalicylic Acid + Simvastatin + Ramipril - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomitapide + Zetia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomitapide + Lipitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomitapide + Fenofibrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha-CD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Raltegravir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL 007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL 007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PPD 10558 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL053 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Hyperlipidemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NanoActive Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pterostilbene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JCH2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WIB-901H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperlipidemia Therapeutics – Drug Profile Updates
Hyperlipidemia Therapeutics – Discontinued Products
Hyperlipidemia Therapeutics - Dormant Products
Hyperlipidemia – Product Development Milestones
Featured News & Press Releases
Mar 19, 2012: Pronova And Takeda Announce Results From Phase III Trial Of TAK-085 At Japanese Circulation Society
Jan 25, 2012: FDA Does Not Approve New Indications For ZETIA
Sep 29, 2011: Pronova And Takeda Announce Submission Of New Drug Application For TAK-085 In Japan For Treatment Of Hyperlipidemia
Jul 25, 2011: Daiichi Sankyo Receives FDA Approval For Welchol sNDA
Jun 23, 2011: Idera Pharmaceuticals Presents Mechanism Of Action Data Of IMO-3100 In Preclinical Model Of Arthritis At FOCIS 2011 Annual Meeting
Nov 17, 2010: Idera Presents Preclinical Data On Mechanism Of Action Of TLR Antagonist Candidate In Model Of Hyperlipidemia At AHA Meeting
Aug 27, 2010: LifeCycle Pharma announces Shionogi Pharma terminates Fenoglide North American commercialization agreement
Aug 17, 2010: KineMed’s Study Of Merck’s Ezetimibe To Join Best Of AHA Specialty Conference 2010
Jul 28, 2010: Abbott Receives FDA Approval For SIMCOR For New Dosage Strengths
Jun 21, 2010: Kowa And Eli Lilly Launch LIVALO In US To Treat Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hyperlipidemia, H1 2012
Products under Development for Hyperlipidemia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
Samyang Corporation, H1 2012
Daewoong Pharmaceutical Co., Ltd., H1 2012
Dr. Reddy's Laboratories Limited, H1 2012
Aegerion Pharmaceuticals, Inc., H1 2012
Idera Pharmaceuticals, Inc., H1 2012
WhanIn Pharmaceutical Co., Ltd., H1 2012
Hanall Pharmaceutical Co., Ltd., H1 2012
Circ Pharma Limited, H1 2012
Ferrer Internacional S.A., H1 2012
Esperion Therapeutics, Inc., H1 2012
CORTRIA Corporation, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Hyperlipidemia Therapeutics – Drug Profile Updates
Hyperlipidemia Therapeutics – Discontinued Products
Hyperlipidemia Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Hyperlipidemia, H1 2012
Products under Development for Hyperlipidemia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Premature Ejaculation – Pipeline Review, H1 2013